SCHEMBL6837223

SCHEMBL6837223

O=C(NCc1ccc(F)cc1)c1ccc2c(c1)C(=O)C(Cc1ccc(Cl)c(F)c1)[S+]([O-])N2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CNR1 P21554 1/20 0.40
PTGER4 P35408 2/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
EPHX2 P34913 1/20 0.39
WDR5 P61964 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
DRD2 P14416 1/20 0.37
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835367 0.94 EPHX2 (0.44) PPARGMAPTLMNATP53CNR1
SCHEMBL6834773 0.93 MAPT (0.42) PPARGMAPTLMNATP53CNR1
SCHEMBL6835340 0.92 CNR1 (0.41) PPARGMAPTLMNATP53CNR1
SCHEMBL6834729 0.91 TP53 (0.44) PPARGMAPTLMNATP53CNR1
SCHEMBL6835368 0.91 ALDH1A1 (0.44) MAPTLMNAHSP90AA1HSP90AB1EPHX2
SCHEMBL6831840 0.89 TP53 (0.42) PPARGMAPTLMNATP53CNR1
SCHEMBL6835302 0.88 MAPT (0.46) MAPTLMNATP53CNR1DRD2
SCHEMBL6835278 0.85 KDM5A (0.35) PTGER4
SCHEMBL6835519 0.84 ALDH1A1 (0.44) MAPTLMNAHSP90AA1HSP90AB1EPHX2
SCHEMBL6831844 0.83 ALDH1A1 (0.45) MAPTLMNAEPHX2HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 PPARG 1261/4885MAPT 2365/4885LMNA 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.